A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Trial Profile

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Final results of the study assessing safety and efficacy, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Results (n=6) from phase Ib portion of the study assessing safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top